Home / BGMS : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does BGMS make money? Does BGMS have pricing power? What's the Earnings Whisper? Will BGMS profit more as the business scales? What is BGMS's management track record? Is BGMS's current price justified?

Bio Green Med Solution, Inc.

$0.9 -$0.51 (-36.34%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$0.87

Day Range

$0.7$1.15

Year Range

$0.57$6.7

Market Cap

4.95M

AVG Volume

2.32M

Trailing/Forward PE

-0.25/0

PEG ratio

Dividend Yield

Next Earnings Date

2026-11-18

Primary Exchange

NASDAQ

Revenue (USD)

BGMS Revenue (USD) by year
Period	Revenue (USD)
2025	747K
2024	43K
2023	420K
2022	0
2021	0
2020	0
2019	0
2018	150K
2017	0
2016	843K

Net Income (USD)

BGMS Net Income (USD) by year
Period	Net Income (USD)
2025	-3M
2024	-11.21M
2023	-22.55M
2022	-21.2M
2021	-18.46M
2020	-8.45M
2019	-7.83M
2018	-7.29M
2017	-7.47M
2016	-11.79M

Operating Income (USD)

BGMS Operating Income (USD) by year
Period	Operating Income (USD)
2025	-8.43M
2024	-14.93M
2023	-24.65M
2022	-22.86M
2021	-22.39M
2020	-10.64M
2019	-9.68M
2018	-9.55M
2017	-9.49M
2016	-14.15M

EBITDA (USD)

BGMS EBITDA (USD) by year
Period	EBITDA (USD)
2025	-8.42M
2024	-14.92M
2023	-26.16M
2022	-27.62M
2021	-22.34M
2020	-10.62M
2019	-9.66M
2018	-9.52M
2017	-9.46M
2016	-14.02M

Cash Flows (USD)

BGMS Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-4.77M
2024	-7.99M
2023	-16.12M
2022	-20.83M
2021	-18.57M
2020	-8.03M
2019	-9.46M
2018	-6.74M
2017	-7.49M
2016	-10.08M

EPS (USD)

BGMS EPS (USD) by year
Period	EPS (USD)
2025	-4.45
2024	-1275.25
2023	-6484.74
2022	-6789.59
2021	-7698.09
2020	-13935.1
2019	-35682.48
2018	-44759.92
2017	-12512
2016	0

Expenses (USD)

BGMS Expenses (USD) by year
Period	Expenses (USD)
2025	8.56M
2024	14.97M
2023	26.29M
2022	27.68M
2021	22.41M
2020	10.73M
2019	9.69M
2018	9.74M
2017	9.51M
2016	15M

Cash & Debt (USD)

BGMS Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	3.5M
2024	3.14M
2023	3.38M
2022	18.34M
2021	36.56M
2020	33.41M
2019	11.88M
2018	17.5M
2017	24.04M
2016	16.65M

Debt ratios

BGMS Debt ratios by year
Period	Debt ratios
2025	0.05
2024	0.03
2023	0.04
2022	0.26
2021	0.7
2020	0.82
2019	0.25
2018	0.36

Margins

BGMS Margins by year
Period	Margins
2025	18.34%
2024	93.02%
2023	96.19%
2018	-2784.67%
2016	-1024.2%
2015	-536.93%

Return on Capital

BGMS Return on Capital by year
Period	Return on Capital
2025	-43.82%
2024	515.73%
2023	-3715.82%
2022	-103.74%
2021	-48.96%
2020	-25.39%
2019	-66.95%
2018	-47.71%
2017	-34.32%
2016	-82.61%

Shares Outstanding

BGMS Shares Outstanding by year
Period	Shares Outstanding
2025	4.61M
2024	38.51K
2023	3.56K
2022	3.48K
2021	2.73K
2020	1.37K
2019	238
2018	168
2017	166
2016	0

Dividends (USD)

BGMS Dividends (USD) by year
Period	Dividends (USD)
2025	36

Book Value Per Share (USD)

BGMS Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	1.49
2024	-56.45
2023	170.6
2022	5866.49
2021	13791.8
2020	24294.38
2019	49147.06
2018	90904.76
2017	131120.48

Total Assets (USD)

BGMS Total Assets (USD) by year
Period	Total Assets (USD)
2025	8.19M
2024	4.09M
2023	8.8M
2022	28.05M
2021	43.14M
2020	36.8M
2019	15.31M
2018	19.82M
2017	26M
2016	19.66M

Free Cash Flow Yield

BGMS Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-21.85%
Sep 26	-22.49%
Sep 26	-21.71%
Aug 26	-38.39%
Aug 26	-38.16%
Aug 26	-36.08%
Aug 26	-34.75%
Jul 26	-37.09%
Jul 26	-36.08%
Jul 26	-34.83%
Jul 26	-36.65%
Jul 26	-31.14%
Jun 26	-54.93%
Jun 26	-43.55%
Jun 26	-42.23%
Jun 26	-22.01%
May 26	-94.13%
May 26	-106.74%
May 26	-103.96%
May 26	-117.66%
May 26	-105.66%
Apr 26	-106.67%
Apr 26	-98.61%
Apr 26	-102.52%
Apr 26	-103.54%
Mar 26	-103.54%
Mar 26	-110.15%
Mar 26	-125.46%
Mar 26	-108.99%
Feb 26	-823.59%
Feb 26	-776.07%
Feb 26	-823.08%
Feb 26	-727.13%
Jan 26	-667.04%
Jan 26	-611.45%
Jan 26	-504.45%
Jan 26	-589.13%
Jan 26	-572.42%
Dec 25	-545.35%
Dec 25	-580.66%
Dec 25	-560.5%
Dec 25	-486.21%
Nov 25	-364.83%
Nov 25	-440.72%
Nov 25	-420.53%
Nov 25	-362.43%
Oct 25	-309.49%
Oct 25	-299.4%
Oct 25	-136.36%
Oct 25	-107.39%
Oct 25	-115.25%
Sep 25	-106.97%
Sep 25	-118.47%
Sep 25	-91.51%

Price to Sales

BGMS Price to Sales by year
Period	Price to Sales
Sep 26	2.7
Sep 26	2.62
Sep 26	2.72
Aug 26	3.08
Aug 26	3.1
Aug 26	3.28
Aug 26	3.4
Jul 26	3.19
Jul 26	3.28
Jul 26	3.39
Jul 26	3.22
Jul 26	3.79
Jun 26	2.15
Jun 26	2.71
Jun 26	2.8
Jun 26	5.37
May 26	6.78
May 26	5.98
May 26	6.14
May 26	5.43
May 26	6.04
Apr 26	5.99
Apr 26	6.48
Apr 26	6.23
Apr 26	6.17
Mar 26	6.17
Mar 26	5.8
Mar 26	5.09
Mar 26	5.86
Feb 26	9.13
Feb 26	9.69
Feb 26	9.14
Feb 26	10.35
Jan 26	11.28
Jan 26	12.3
Jan 26	14.91
Jan 26	12.77
Jan 26	13.14
Dec 25	13.79
Dec 25	12.95
Dec 25	13.42
Dec 25	15.47
Nov 25	239.18
Nov 25	198
Nov 25	207.5
Nov 25	240.76
Oct 25	281.95
Oct 25	291.45
Oct 25	639.92
Oct 25	812.57
Oct 25	757.14
Sep 25	815.74
Sep 25	736.54
Sep 25	953.55

Price to Book

BGMS Price to Book by year
Period	Price to Book
Sep 26	0.7
Sep 26	0.68
Sep 26	0.71
Aug 26	0.69
Aug 26	0.7
Aug 26	0.74
Aug 26	0.77
Jul 26	0.72
Jul 26	0.74
Jul 26	0.77
Jul 26	0.73
Jul 26	0.86
Jun 26	0.49
Jun 26	0.61
Jun 26	0.63
Jun 26	1.21
May 26	0.74
May 26	0.65
May 26	0.67
May 26	0.59
May 26	0.66
Apr 26	0.65
Apr 26	0.71
Apr 26	0.68
Apr 26	0.67
Mar 26	0.67
Mar 26	0.63
Mar 26	0.56
Mar 26	0.64
Feb 26	0.1
Feb 26	0.11
Feb 26	0.1
Feb 26	0.12
Jan 26	0.13
Jan 26	0.14
Jan 26	0.17
Jan 26	0.15
Jan 26	0.15
Dec 25	0.16
Dec 25	0.15
Dec 25	0.15
Dec 25	0.18
Nov 25	0.66
Nov 25	0.55
Nov 25	0.57
Nov 25	0.66
Oct 25	0.78
Oct 25	0.8
Oct 25	1.76
Oct 25	2.24
Oct 25	2.09
Sep 25	2.25
Sep 25	2.03
Sep 25	2.63

No video analysis for this stock yet. Request one from our team.

News: BGMS

globenewswire.com · 8 Sep 2026

EQUITY ALERT: The M&A Class Action Firm Launches Inquiry for the Merger— ATKR, BGMS, BOW and FTHM

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

globenewswire.com · 12 Aug 2026

BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced second quarter financial results and provided a business update.

prnewswire.com · 27 Jul 2026

Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

defenseworld.net · 26 Jul 2026

Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ: BGMS - Get Free Report) and Peak Pharmaceuticals (OTCMKTS:PKPH - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings. Profitability This table compares Cyclacel Pharmaceuticals and